The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-10. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Flyorov is also known for the discovery of spontaneous fission with Konstantin Petrzhak. IUPAC approved the name in May, 2012 and the naming ceremony for flerovium and livermorium was held on 24 October 2012 in Moscow. Other proposals included atlantisium (An, a reference via Atlantis to the island of stability), lazarevium (Lz, in honor of Yuri Lazarev), and oganessium (Og, in honor of Yuri Oganessian). In a 2015 interview with Oganessian, the host, in preparation to ask a question, said, "You said you had dreamed to name [an element] after your teacher Georgy Flyorov." Without letting the host finish, Oganessian repeatedly said, "I did."
Banlieue Triste was already attracting attention, wrote Frank Colombani of Le Monde, and the band were therefore courted by the Spinefarm Records label. Spinefarm Records released the album on 28 September 2018 in all territories outside France. A special double-vinyl edition of the album was released simultaneously, following the signing of the quartet Chanut, Thépegnier, Hanvic, and Toufouti to Spinefarm Records, thereby guaranteeing worldwide distribution for their future recordings. Hope /// Dope /// Rope, This Is Not Supposed To Be Positive and Banlieue Triste "are part of a whole", thus constituting a "trilogy", Chanut said. Banlieue Triste led the band to appear on the French television channel Canal+ for a short concert on the programme L'album de la Semaine (lit. 'Album of the Week'), to be broadcast on FIP and France Inter, and to be featured in articles in the general-interest press. While the band frequently toured the Upper France region during the winter of 2018, they opened for Zeal & Ardor at L'Aéronef in Lille and for Samael in Dunkirk. They regularly performed in Belgium and the Netherlands because their manager was based in Lille. The single "Lost Brothel" was released in July 2019, ahead of a four-track EP titled Bus de Nuit (lit. 'Night Bus'). On 16 August 2019, Hangman's Chair performed at the Psycho Las Vegas festival in Nevada, US. A joint performance by Hangman's Chair and the post-black metal band Regarde Les Hommes Tomber (lit.
The yellow pulp, which contains the seeds, is naturally sweet and is processed into a valuable carbohydrate food. The seeds are processed into a seasoning, known as sikomu and dodowa/ dawadawa among the Yoruba and Hausa people respectively, and sunbala in the Inner Niger Delta. The pulp is also used to make beverages. The seeds of the locust bean are the most valuable part of the plant. They are high in lipids (29%), protein (35%), carbohydrates (16%), and are a good source of fat and calcium for rural dwellers. The seed is first cooked to remove the seed coat and then fermented to produce the desired result. Seeds can then be pounded into powder, then formed into cakes. In a study conducted on the fermentation of dawadawa, it was found that Gmelina arborea and banana leaves accelerated fermentation of seeds, while increasing fat, protein and moisture content, but also decreasing carbohydrate content.
Pakistan's nuclear policy became fixated on India because India refused to join the Non-proliferation Treaty and remained open to nuclear weapons. Impetus by Indian actions spurred Pakistan's nuclear research. After nuclear weapons construction was started by President Zulfikar Ali Bhutto's command, the chair of Pakistan Atomic Energy Commission Usmani quit in objection. The 1999 war between Pakistan and India occurred after both acquired nuclear weapons. It is believed by some that nuclear weapons are the reason a big war has not broken out in the subcontinent. India and Pakistan still have a risk of nuclear conflict on the issue of war over Kashmir. Nuclear capability deliverable by sea were claimed by Pakistan in 2012. The aim was to achieve a "minimum credible deterrence". Pakistan's nuclear program culminated in the tests at Chagai. One of the aims of Pakistan's programs is fending off potential annexation and maintaining independence. A key development in nuclear warfare throughout the 2000s and early 2010s is the proliferation of nuclear weapons to the developing world, with India and Pakistan both publicly testing several nuclear devices, and North Korea conducting an underground nuclear test on October 9, 2006. The U.S. Geological Survey measured a 4.2 magnitude earthquake in the area where the North Korean test is said to have occurred. A further test was announced by the North Korean government on May 25, 2009.
Sources: en.wikipedia.org
By the second half of the 20th century, several large-scale industrial processes had been developed in which nitriles were either produced or utilized. An important example is the development of polyamides (polyamide 6.6) in the 1930s, as adiponitrile is a key intermediate in its manufacture and is produced by hydrocyanation of butadiene with hydrogen cyanide. Acrylonitrile polymers have been known since the 1920s but gained greater importance as synthetic fibers toward the late 1940s. Superglues based on cyanoacrylates have also been available since the late 1940s.
Convergent evolution is the independent evolution of similar features in species of different lineages. Convergent evolution creates analogous structures that have similar form or function but were not present in the last common ancestor of those groups. The cladistic term for the same phenomenon is homoplasy. The recurrent evolution of flight is a classic example, as flying insects, birds, pterosaurs, and bats have independently evolved the useful capacity of flight. Functionally similar features that have arisen through convergent evolution are analogous, whereas homologous structures or traits have a common origin but can have dissimilar functions. Bird, bat, and pterosaur wings are analogous structures, but their forelimbs are homologous, sharing an ancestral state despite serving different functions. The opposite of convergent evolution is divergent evolution, where related species evolve different traits. Convergent evolution is similar to parallel evolution, which occurs when two independent species evolve in the same direction and thus independently acquire similar characteristics; for instance, gliding frogs have evolved in parallel from multiple types of tree frog. Many instances of convergent evolution are known in plants, including the repeated development of C4 photosynthesis, seed dispersal by fleshy fruits adapted to be eaten by animals, and carnivory.
=== Multiple equilibria === Two or more equilibria can exist at the same time. When this is so, equilibrium constants can be ascribed to individual equilibria, but they are not always unique. For example, three equilibrium constants can be defined for a dibasic acid, H2A.
In July 2020, the US National Institutes of Health stated "There is insufficient evidence to recommend for or against using vitamin D supplementation for the prevention or treatment of COVID-19." In that same year, the UK National Institute for Health and Care Excellence (NICE) position was to not recommend to offer a vitamin D supplement to people solely to prevent or treat COVID-19. NICE updated its position in 2022 to "Do not use vitamin D to treat COVID-19 except as part of a clinical trial." Both organizations included recommendations to continue the previously established recommendations on vitamin D supplementation for other reasons, such as bone and muscle health, as applicable. Both organizations noted that more people may require supplementation due to lower amounts of sun exposure during the pandemic. Vitamin D deficiency and insufficiency have been associated with adverse outcomes in COVID-19. Supplementation trials, mostly large, single, oral dose upon hospital admission, reported lower subsequent transfers to intensive care and to all-cause mortality.
=== Pharmacokinetics === When used as an injectable it typically begins working within four minutes and lasts for half an hour to three hours. Lidocaine is about 95% metabolized (dealkylated) in the liver mainly by CYP3A4 to the pharmacologically active metabolites monoethylglycinexylidide (MEGX) and then subsequently to the inactive glycine xylidide. MEGX has a longer half-life than lidocaine, but also is a less potent sodium channel blocker. The volume of distribution is 1.1 L/kg to 2.1 L/kg, but congestive heart failure can decrease it. About 60% to 80% circulates bound to the protein alpha1 acid glycoprotein. The oral bioavailability is 35% and the topical bioavailability is 3%. Lidocaine efficacy may be reduced in tissues that are inflamed, due to competing inflammatory mediators. The elimination half-life of lidocaine is biphasic and around 90 min to 120 min in most people. This may be prolonged in people with hepatic impairment (average 343 min) or congestive heart failure (average 136 min). Lidocaine is excreted in the urine (90% as metabolites and 10% as unchanged drug).
Sources: en.wikipedia.org
April 30: Start of occupation of Trieste by Yugoslav forces, although challenged by the 2nd New Zealand Division under General Freyberg and the city remained part of Italy. Cox said that it was the first major confrontation of the Cold War and was the one corner of Europe where no demarcation line had been agreed upon in advance by the Allies. May 2: The Italian Civil War ends. May 8: Germany surrenders. End of World War II in Europe (V-E Day). July 24: Potsdam Conference - At the Potsdam Conference, Truman informs Stalin that the United States has nuclear weapons. August 6: Atomic bombings of Hiroshima and Nagasaki - Truman follows the advice of Secretary of War Henry L. Stimson and gives permission for the world's first military use of an atomic weapon, against the Japanese city of Hiroshima. August 8: The USSR honors its agreement to declare war on Japan within three months of the victory in Europe, and invades Manchuria. August 9: With no Japanese response to his ultimatums, Truman gives permission for the world's second and last military use of an atomic weapon, against the Japanese city of Nagasaki (Kokura was the original target). August 12: Japanese forces in Korea surrender to Soviet and American armies. August 17: Proclamation of Indonesian Independence - The Dutch East Indies declares its independence from the Dutch. This marked the beginning of the Indonesian National Revolution.
=== Scientific attempts to quantify the pain of freeze branding === Even though current scientific methodologies cannot adequately distinguish between reflex response and the lay understanding of pain, scientific methods are well suited to comparing two stimuli and making a reasonable assertion as to which is objectively less noxious. Freeze branding has frequently been hailed as a less noxious means of permanently denoting ownership of livestock. Despite this, the claim that freeze branding is inherently less painful than hot branding has been challenged. These challenges provoked scientific studies to determine the matter objectively and they have attempted to measure the pain experienced by animals during and after their branding.
== Signs and symptoms == The key sign of metabolic syndrome is central obesity, also known as visceral, male-pattern or apple-shaped adiposity. It is characterized by adipose tissue accumulation predominantly around the waist and trunk. Other signs of metabolic syndrome include high blood pressure, decreased fasting serum HDL cholesterol, elevated fasting serum triglyceride level, impaired fasting glucose, insulin resistance, or prediabetes. Associated conditions include hyperuricemia; fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease; polyendocrine metabolic ovarian syndrome in women and erectile dysfunction in men; and acanthosis nigricans.
=== Synthetic steroids and sterols === A variety of synthetic steroids and sterols have also been contrived. Most are steroids, but some nonsteroidal molecules can interact with the steroid receptors because of a similarity of shape. Some synthetic steroids are weaker or stronger than the natural steroids whose receptors they activate. Some examples of synthetic steroid hormones:
=== Physical stability === Micromeritic properties of a particle, i.e. the particle size in a formulation, influence the physical stability of the suspensions and emulsions. The smaller the size of the particle, the better the physical stability of the dosage form owing to the Brownian motion of the particles in the dispersion.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.